GRAd-COV2 Uses, Dosage, Side Effects and more

GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2). Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses.

Trade Name GRAd-COV2
Generic GRAd-COV2
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share